Subscribe
istock-643956998_jirsak
jirsak / iStockphoto.com
5 December 2018Americas

Allele Biotech partners with Scientist.com to develop nanoantibodies

US-based  Allele Biotechnology & Pharmaceuticals, a preclinical-stage biopharmaceutical company, has teamed up with a scientific e-commerce marketplace network in efforts to develop nanoantibodies for therapeutic applications.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Allele drops COVID-19 protein suit against Pfizer, BioNTech
6 January 2022   Biotech Allele has dropped its lawsuit accusing Pfizer and BioNTech of infringing technology covering a fluorescent protein used in COVID-19 vaccines.
Big Pharma
Sanofi to acquire Ablynx for €3.9bn
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).


Editor's picks

BMS blocks biosimilar version of blockbuster cancer drug in India
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

Editor's picks

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

More on this story

Biotechnology
Allele drops COVID-19 protein suit against Pfizer, BioNTech
6 January 2022   Biotech Allele has dropped its lawsuit accusing Pfizer and BioNTech of infringing technology covering a fluorescent protein used in COVID-19 vaccines.
Big Pharma
Sanofi to acquire Ablynx for €3.9bn
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).

More on this story

Biotechnology
Allele drops COVID-19 protein suit against Pfizer, BioNTech
6 January 2022   Biotech Allele has dropped its lawsuit accusing Pfizer and BioNTech of infringing technology covering a fluorescent protein used in COVID-19 vaccines.
Big Pharma
Sanofi to acquire Ablynx for €3.9bn
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).

More features

UPC hands rare default win to Insulet, bans insulin pump in EU
GSK loses appeal over purple inhaler TM in Europe
Astellas defends Xtandi patent as court rejects generics’ appeal
Jury sides with Allergan in $56M Botox tech feud
Novartis fails latest bid to block Entresto copies
BMS blocks biosimilar version of blockbuster cancer drug in India
WATCH: Protecting life science innovations involving big data, AI and machine learning
AbbVie blocks Humira antitrust suit